TD Asset Management Inc Has $8.62 Million Stock Position in Abivax SA Sponsored ADR $ABVX

TD Asset Management Inc increased its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 37.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,902 shares of the company’s stock after purchasing an additional 17,416 shares during the period. TD Asset Management Inc’s holdings in Abivax were worth $8,618,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ABVX. UBS Group AG grew its stake in Abivax by 2,561.0% during the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. acquired a new stake in Abivax during the third quarter worth approximately $263,698,000. Paradigm Biocapital Advisors LP acquired a new stake in Abivax during the third quarter worth approximately $132,800,000. TCG Crossover Management LLC grew its stake in Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock worth $603,774,000 after purchasing an additional 1,055,000 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in Abivax during the third quarter worth approximately $84,900,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Performance

Shares of Abivax stock opened at $102.72 on Wednesday. Abivax SA Sponsored ADR has a 52 week low of $5.69 and a 52 week high of $148.83. The stock has a 50 day moving average price of $116.66 and a two-hundred day moving average price of $119.58. The stock has a market capitalization of $8.19 billion, a PE ratio of -19.72 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on ABVX shares. Citizens Jmp raised their target price on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research note on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Tuesday, June 2nd. Morgan Stanley reduced their price objective on Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research note on Tuesday, June 2nd. Wall Street Zen raised Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Finally, Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Twelve analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $130.08.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.